MYC and Familial prostate cancer: While both c‐Myc‐i8 (IC50 of 94.0 μM) and c‐Myc‐i10 (11.7 μM) exhibited considerable efficacy, the latter showed an eight‐fold improvement in its performance against prostate cancer compared to 10058‐F4.